Shantha Of India Unlikely To Reach Buyer Sanofi's Sales Goal
This article was originally published in PharmAsia News
Executive Summary
India's Shantha Biotechnics has failed to provide buyer Sanofi-Aventis of Franace the sales it counted on when it bought the biotech for $602 million